Limits...
Open-label, Randomized Crossover Study Between Telmisartan and Valsartan on Improving Insulin Resistance and Adipocytokines in Nondiabetic Patients with Mild Hypertension.

Ohbayashi H, Minatoguchi S, Aoyama T, Fujiwara H - J Rural Med (2010)

Bottom Line: Serum adiponectin did not increase in either treatment group.Serum hsCRP levels also significantly decreased in the high hsCRP subjects (>/=0.1) of both treatment groups (p=0.044 and p=0.015, respectively).Telmisartan significantly improved insulin resistance, possibly through the effect on PPAR-gamma, while both telmisartan and valsartan significantly decreased serum leptin levels in female groups and hsCRP in both genders, suggesting no significantly different effects on adipocytokines by either drug in nondiabetic patients with mild hypertension.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, JA Gifu Tohno-Kousei Hospital, Japan ; Second Department of Internal Medicine, Gifu University School of Medicine, Japan.

ABSTRACT

Objective: The comparative effect of telmisartan and valsartan upon insulin resistance and adipocytokines in nondiabetic patients with mild hypertension is unclear.

Methods: Fifty nondiabetic patients with untreated mild hypertension were randomly assigned to telmisartan (40 mg/day) and valsartan (80 mg/day) groups and were switched in a crossover manner at 3-month intervals. Serum leptin, adiponectin, hsCRP and the HOMA-R were measured before and at 3 months during each treatment period.

Results: The HOMA-R significantly improved over the 3 months in the high insulin resistance group (HOMA-R>/=2.5) during the telmisartan treatment period (p=0.042), but not during the valsartan period. Both telmisartan and valsartan significantly decreased serum leptin levels in each female group during each treatment period (p<0.001 and p<0.001, respectively), but not in the male groups. Serum adiponectin did not increase in either treatment group. Serum hsCRP levels also significantly decreased in the high hsCRP subjects (>/=0.1) of both treatment groups (p=0.044 and p=0.015, respectively).

Conclusions: Telmisartan significantly improved insulin resistance, possibly through the effect on PPAR-gamma, while both telmisartan and valsartan significantly decreased serum leptin levels in female groups and hsCRP in both genders, suggesting no significantly different effects on adipocytokines by either drug in nondiabetic patients with mild hypertension.

No MeSH data available.


Related in: MedlinePlus

Time-course changes in systolic and diastolic blood pressures over the studyperiod. Statistical significance: *p<0.05, **p<0.01 and ***p<0.001 comparedwith the values at the start of the study.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4309358&req=5

fig_002: Time-course changes in systolic and diastolic blood pressures over the studyperiod. Statistical significance: *p<0.05, **p<0.01 and ***p<0.001 comparedwith the values at the start of the study.

Mentions: Ultimately, 42 nondiabetic patients with mild hypertension completed the study (Figure 1B). Patient characteristics are shown inTable 1. There was no statisticalsignificance concerning the major indexes between the initial telmisartan and initialvalsartan groups at enrollment in the study. During the study, the 42 subjects did notcomplain of any side effects.


Open-label, Randomized Crossover Study Between Telmisartan and Valsartan on Improving Insulin Resistance and Adipocytokines in Nondiabetic Patients with Mild Hypertension.

Ohbayashi H, Minatoguchi S, Aoyama T, Fujiwara H - J Rural Med (2010)

Time-course changes in systolic and diastolic blood pressures over the studyperiod. Statistical significance: *p<0.05, **p<0.01 and ***p<0.001 comparedwith the values at the start of the study.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4309358&req=5

fig_002: Time-course changes in systolic and diastolic blood pressures over the studyperiod. Statistical significance: *p<0.05, **p<0.01 and ***p<0.001 comparedwith the values at the start of the study.
Mentions: Ultimately, 42 nondiabetic patients with mild hypertension completed the study (Figure 1B). Patient characteristics are shown inTable 1. There was no statisticalsignificance concerning the major indexes between the initial telmisartan and initialvalsartan groups at enrollment in the study. During the study, the 42 subjects did notcomplain of any side effects.

Bottom Line: Serum adiponectin did not increase in either treatment group.Serum hsCRP levels also significantly decreased in the high hsCRP subjects (>/=0.1) of both treatment groups (p=0.044 and p=0.015, respectively).Telmisartan significantly improved insulin resistance, possibly through the effect on PPAR-gamma, while both telmisartan and valsartan significantly decreased serum leptin levels in female groups and hsCRP in both genders, suggesting no significantly different effects on adipocytokines by either drug in nondiabetic patients with mild hypertension.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, JA Gifu Tohno-Kousei Hospital, Japan ; Second Department of Internal Medicine, Gifu University School of Medicine, Japan.

ABSTRACT

Objective: The comparative effect of telmisartan and valsartan upon insulin resistance and adipocytokines in nondiabetic patients with mild hypertension is unclear.

Methods: Fifty nondiabetic patients with untreated mild hypertension were randomly assigned to telmisartan (40 mg/day) and valsartan (80 mg/day) groups and were switched in a crossover manner at 3-month intervals. Serum leptin, adiponectin, hsCRP and the HOMA-R were measured before and at 3 months during each treatment period.

Results: The HOMA-R significantly improved over the 3 months in the high insulin resistance group (HOMA-R>/=2.5) during the telmisartan treatment period (p=0.042), but not during the valsartan period. Both telmisartan and valsartan significantly decreased serum leptin levels in each female group during each treatment period (p<0.001 and p<0.001, respectively), but not in the male groups. Serum adiponectin did not increase in either treatment group. Serum hsCRP levels also significantly decreased in the high hsCRP subjects (>/=0.1) of both treatment groups (p=0.044 and p=0.015, respectively).

Conclusions: Telmisartan significantly improved insulin resistance, possibly through the effect on PPAR-gamma, while both telmisartan and valsartan significantly decreased serum leptin levels in female groups and hsCRP in both genders, suggesting no significantly different effects on adipocytokines by either drug in nondiabetic patients with mild hypertension.

No MeSH data available.


Related in: MedlinePlus